Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Google Secures Pentagon AI Deal for Classified Projects 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
SEATTLE, Feb. 12, 2016 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release fourth quarter 2015 financial results after the close of trading on Monday, February 29, 2016. Company management will host a conference call beginning at 4:30pm ET to discuss those results and to provide a business update.
Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers. Please reference Conference ID: 38816043. To listen to a live webcast, please visit the investor relations section of the company’s website at: www.nanostring.com.
A replay of the call will be available beginning February 29, 2016 at 7:30pm ET through midnight on March 1, 2016. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 38816043. The webcast will also be available on the company’s website for one year following the completion of the call.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
Investor Contact: Leigh Salvo of Westwicke Partners For NanoString Technologies [email protected] 415-513-1281
